Homepage

Syntrix Clinical Trial of Omnitram Succeeds on Primary Endpoints

Syntrix announced that the Phase 1B study investigating Omnitram for pain in healthy subjects met its primary endpoints for pharmacokinetics, safety, and analgesia.  The study was performed with Syntrix collaborators at PRA International and the IIT Research Institute.  The study was funded by a $1.8 million grant from the National Institute on Drug Abuse (NIDA) […]

Syntrix Publication in Bioorganic & Medicinal Chemistry Letters

Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Bioorganic & Medicinal Chemistry Letters.  Abstract: Blockade of undesired neutrophil migration to sites of inflammation remains an area of substantial pharmaceutical interest.  To effect this blockade, a validated therapeutic target is antagonism of the chemokine receptor CXCR2.  Herein we report the discovery […]

Syntrix Wins U.S. Patent 8,993,541: Aminopyrimidine Carboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Zebala, John A. (Sammamish, WA); and Schuler, Aaron D. (Auburn, WA).  Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, […]